Alzheimer's disease is type 3 diabetes-evidence reviewed.

Obesity- and aging-induced excess of central transforming growth factor-β potentiates diabetic development via an RNA stress response. Nat Med (2014) 2.33

Insulin resistance and Alzheimer's disease. BMB Rep (2009) 1.49

Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease. J Cereb Blood Flow Metab (2013) 1.45

Type 2 diabetes and cognitive impairment: linking mechanisms. J Alzheimers Dis (2012) 1.28

Time for new guidelines in advanced diabetes care: Paradigm change from delayed interventional approach to predictive, preventive & personalized medicine. EPMA J (2010) 1.24

Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. Curr Opin Investig Drugs (2009) 1.21

Brain metabolic dysfunction at the core of Alzheimer's disease. Biochem Pharmacol (2013) 1.21

Glucose metabolism and pancreatic defects in spinal muscular atrophy. Ann Neurol (2012) 1.17

Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's disease. J Alzheimers Dis (2009) 1.15

Emerging applications of metabolomics in drug discovery and precision medicine. Nat Rev Drug Discov (2016) 1.14

Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. Acta Neuropathol (2015) 1.11

Altered expression of diabetes-related genes in Alzheimer's disease brains: the Hisayama study. Cereb Cortex (2013) 1.09

Insulin, cognition, and dementia. Eur J Pharmacol (2013) 1.06

Reduction in BACE1 decreases body weight, protects against diet-induced obesity and enhances insulin sensitivity in mice. Biochem J (2012) 1.04

Brain insulin signaling: a key component of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes. Neurobiol Learn Mem (2011) 1.02

Food reward functions as affected by obesity and bariatric surgery. Int J Obes (Lond) (2011) 1.01

Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes (2014) 1.01

Diabetes is associated with cerebrovascular but not Alzheimer's disease neuropathology. Alzheimers Dement (2016) 0.99

Insulin in the brain: its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer's disease. Front Endocrinol (Lausanne) (2014) 0.98

From integrative disease modeling to predictive, preventive, personalized and participatory (P4) medicine. EPMA J (2013) 0.98

Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer's disease and tauopathies. Acta Neuropathol (2014) 0.97

Cinnamon: potential role in the prevention of insulin resistance, metabolic syndrome, and type 2 diabetes. J Diabetes Sci Technol (2010) 0.97

Dissecting the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in colon, breast, and lung carcinogenesis. Cancer Metastasis Rev (2011) 0.95

Nitrosamine exposure exacerbates high fat diet-mediated type 2 diabetes mellitus, non-alcoholic steatohepatitis, and neurodegeneration with cognitive impairment. Mol Neurodegener (2009) 0.95

Mechanisms underlying insulin deficiency-induced acceleration of β-amyloidosis in a mouse model of Alzheimer's disease. PLoS One (2012) 0.94

Type 2 diabetes mellitus, dyslipidemia, and Alzheimer's disease. J Alzheimers Dis (2010) 0.93

Type 2 diabetes mellitus and Alzheimer's disease. World J Diabetes (2014) 0.93

Triangulated mal-signaling in Alzheimer's disease: roles of neurotoxic ceramides, ER stress, and insulin resistance reviewed. J Alzheimers Dis (2012) 0.91

Neuropharmacological review of the nootropic herb Bacopa monnieri. Rejuvenation Res (2013) 0.91

Ceramide-mediated insulin resistance and impairment of cognitive-motor functions. J Alzheimers Dis (2010) 0.91

Mechanisms of nitrosamine-mediated neurodegeneration: potential relevance to sporadic Alzheimer's disease. J Alzheimers Dis (2009) 0.91

New therapeutic approaches for Alzheimer's disease and cerebral amyloid angiopathy. Front Aging Neurosci (2014) 0.89

Associations between apolipoprotein E genotypes and serum levels of glucose, cholesterol, and triglycerides in a cognitively normal aging Han Chinese population. Clin Interv Aging (2014) 0.89

Early limited nitrosamine exposures exacerbate high fat diet-mediated type 2 diabetes and neurodegeneration. BMC Endocr Disord (2010) 0.89

PTEN, a widely known negative regulator of insulin/PI3K signaling, positively regulates neuronal insulin resistance. Mol Biol Cell (2012) 0.89

Evaluating the Association between Diabetes, Cognitive Decline and Dementia. Int J Environ Res Public Health (2015) 0.87

Obesity, insulin resistance, and Alzheimer's disease. Obesity (Silver Spring) (2012) 0.87

Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis. Nat Commun (2016) 0.86

Brain gene expression of a sporadic (icv-STZ Mouse) and a familial mouse model (3xTg-AD mouse) of Alzheimer's disease. PLoS One (2012) 0.86

Caloric restriction can improve learning ability in C57/BL mice via regulation of the insulin-PI3K/Akt signaling pathway. Neurol Sci (2014) 0.85

Acute hypoglycemia causes depressive-like behaviors in mice. Metabolism (2011) 0.85

Consequences of Aberrant Insulin Regulation in the Brain: Can Treating Diabetes be Effective for Alzheimer's Disease. Curr Neuropharmacol (2011) 0.85

Neuronal LRP1 regulates glucose metabolism and insulin signaling in the brain. J Neurosci (2015) 0.84

Human ApoE Isoforms Differentially Modulate Glucose and Amyloid Metabolic Pathways in Female Brain: Evidence of the Mechanism of Neuroprotection by ApoE2 and Implications for Alzheimer's Disease Prevention and Early Intervention. J Alzheimers Dis (2015) 0.84

Dysfunctional pro-ceramide, ER stress, and insulin/IGF signaling networks with progression of Alzheimer's disease. J Alzheimers Dis (2012) 0.84

Neuropsychological benefits of stationary bike exercise and a cybercycle exergame for older adults with diabetes: an exploratory analysis. J Diabetes Sci Technol (2012) 0.83

The link between iron, metabolic syndrome, and Alzheimer's disease. J Neural Transm (Vienna) (2010) 0.82

Bio-informatics analysis of a gene co-expression module in adipose tissue containing the diet-responsive gene Nnat. BMC Syst Biol (2010) 0.82

Increased Spontaneous Central Bleeding and Cognition Impairment in APP/PS1 Mice with Poorly Controlled Diabetes Mellitus. Mol Neurobiol (2015) 0.82

A systematic review of type 2 diabetes mellitus and hypertension in imaging studies of cognitive aging: time to establish new norms. Front Aging Neurosci (2014) 0.82

Altered gene expression profiles in the hippocampus and prefrontal cortex of type 2 diabetic rats. BMC Genomics (2012) 0.81

The saturated fatty acid, palmitic acid, induces anxiety-like behavior in mice. Metabolism (2014) 0.81

Protection against the synaptic targeting and toxicity of Alzheimer's-associated Aβ oligomers by insulin mimetic chiro-inositols. FASEB J (2012) 0.81

Insulin sensitizers improve learning and attenuate tau hyperphosphorylation and neuroinflammation in 3xTg-AD mice. J Neural Transm (Vienna) (2014) 0.81

Amylin at the interface between metabolic and neurodegenerative disorders. Front Neurosci (2015) 0.81

Brain aging and AD-like pathology in streptozotocin-induced diabetic rats. J Diabetes Res (2014) 0.80

Molecular and biochemical trajectories from diabetes to Alzheimer's disease: A critical appraisal. World J Diabetes (2015) 0.80

Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal. Biochim Biophys Acta (2016) 0.80

Cinnamon counteracts the negative effects of a high fat/high fructose diet on behavior, brain insulin signaling and Alzheimer-associated changes. PLoS One (2013) 0.80

Machine Learning and Data Mining Methods in Diabetes Research. Comput Struct Biotechnol J (2017) 0.80

Intranasal insulin therapy for cognitive impairment and neurodegeneration: current state of the art. Expert Opin Drug Deliv (2013) 0.79

Unraveling Alzheimer's: Making Sense of the Relationship between Diabetes and Alzheimer's Disease1. J Alzheimers Dis (2016) 0.79

Metabolic relationship between diabetes and Alzheimer's Disease affected by Cyclo(His-Pro) plus zinc treatment. BBA Clin (2016) 0.78

Short-Term High-Fat Diet (HFD) Induced Anxiety-Like Behaviors and Cognitive Impairment Are Improved with Treatment by Glyburide. Front Behav Neurosci (2016) 0.78

Systems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor System. Front Endocrinol (Lausanne) (2014) 0.78

Parameters of glucose metabolism and the aging brain: a magnetization transfer imaging study of brain macro- and micro-structure in older adults without diabetes. Age (Dordr) (2015) 0.78

Magnetic Optical Microarray Imager for Diagnosing Type of Diabetes in Clinical Blood Serum Samples. ACS Sens (2016) 0.78

Molecular targets of the multifunctional iron-chelating drug, M30, in the brains of mouse models of type 2 diabetes mellitus. Br J Pharmacol (2014) 0.78

Magnesium protects cognitive functions and synaptic plasticity in streptozotocin-induced sporadic Alzheimer's model. PLoS One (2014) 0.78

The Association Between Diabetes and Dementia Among Elderly Individuals: A Nationwide Inpatient Sample Analysis. J Geriatr Psychiatry Neurol (2016) 0.78

Targeting Alzheimer's Disease Neuro-Metabolic Dysfunction with a Small Molecule Nuclear Receptor Agonist (T3D-959) Reverses Disease Pathologies. J Alzheimers Dis Parkinsonism (2016) 0.77

A network model of genomic hormone interactions underlying dementia and its translational validation through serendipitous off-target effect. J Transl Med (2013) 0.77

Metabolic derangements mediate cognitive impairment and Alzheimer's disease: role of peripheral insulin-resistance diseases. Panminerva Med (2012) 0.77

Insulin in the nervous system and the mind: Functions in metabolism, memory, and mood. Mol Metab (2016) 0.77

Synchronizing an aging brain: can entraining circadian clocks by food slow Alzheimer's disease? Front Aging Neurosci (2014) 0.77

Alternate Phosphorylation/O-GlcNAc Modification on Human Insulin IRSs: A Road towards Impaired Insulin Signaling in Alzheimer and Diabetes. Adv Bioinformatics (2014) 0.77

Linking insulin with Alzheimer's disease: emergence as type III diabetes. Neurol Sci (2015) 0.77

Epigenomic and metabolic responses of hypothalamic POMC neurons to gestational nicotine exposure in adult offspring. Genome Med (2016) 0.76

Key Targets for Multi-Target Ligands Designed to Combat Neurodegeneration. Front Neurosci (2016) 0.76

Metformin Prevents Nigrostriatal Dopamine Degeneration Independent of AMPK Activation in Dopamine Neurons. PLoS One (2016) 0.76

Short-lived diabetes in the young-adult ZDF rat does not exacerbate neuronal Ca(2+) biomarkers of aging. Brain Res (2014) 0.76

Neuroprotective effects of treadmill exercise on BDNF and PI3-K/Akt signaling pathway in the cortex of transgenic mice model of Alzheimer's disease. J Exerc Nutrition Biochem (2013) 0.76

Unified theory of Alzheimer's disease (UTAD): implications for prevention and curative therapy. J Mol Psychiatry (2016) 0.76

Novel Roles for the Insulin-Regulated Glucose Transporter-4 in Hippocampally Dependent Memory. J Neurosci (2016) 0.76

Type 2 diabetes and quality of life. World J Diabetes (2017) 0.75

Use of laser-induced breakdown spectroscopy for the detection of glycemic elements in Indian medicinal plants. Evid Based Complement Alternat Med (2013) 0.75

Effects of pioglitazone or exercise in older adults with mild cognitive impairment and insulin resistance: a pilot study. Dement Geriatr Cogn Dis Extra (2015) 0.75

Association of Increased Serum ACE Activity with Logical Memory Ability in Type 2 Diabetic Patients with Mild Cognitive Impairment. Front Behav Neurosci (2016) 0.75

Temporal dystrophic remodeling within the intrinsic cardiac nervous system of the streptozotocin-induced diabetic rat model. Acta Neuropathol Commun (2014) 0.75

A Systematic Review of Intervention Studies Examining Nutritional and Herbal Therapies for Mild Cognitive Impairment and Dementia Using Neuroimaging Methods: Study Characteristics and Intervention Efficacy. Evid Based Complement Alternat Med (2017) 0.75

Imaging in pancreatic disease. Nat Rev Gastroenterol Hepatol (2016) 0.75

High glucose upregulates BACE1-mediated Aβ production through ROS-dependent HIF-1α and LXRα/ABCA1-regulated lipid raft reorganization in SK-N-MC cells. Sci Rep (2016) 0.75

Concurrence of High Fat Diet and APOE Gene Induces Allele Specific Metabolic and Mental Stress Changes in a Mouse Model of Alzheimer's Disease. Front Behav Neurosci (2016) 0.75

Protection by beta-Hydroxybutyric acid against insulin glycation, lipid peroxidation and microglial cell apoptosis. Daru (2015) 0.75

Finding needles in a haystack: application of network analysis and target enrichment studies for the identification of potential anti-diabetic phytochemicals. PLoS One (2014) 0.75

Oxytocin Protects against Stress-Induced Cell Death in Murine Pancreatic β-Cells. Sci Rep (2016) 0.75

A link between type 2 diabetes and brain function. JAAPA (2013) 0.75

The impact of hippocampal lesions on trace-eyeblink conditioning and forebrain-cerebellar interactions. Behav Neurosci (2015) 0.75

Metabolism-Centric Overview of the Pathogenesis of Alzheimer's Disease. Yonsei Med J (2017) 0.75

[Diabetes mellitus and cognitive decline]. Wien Med Wochenschr (2011) 0.75

Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature (1985) 13.79

Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature (1995) 11.61

Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science (1997) 11.48

The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res (2001) 6.59

Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature (1991) 6.50

Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci U S A (1998) 5.98

Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol (1997) 4.70

Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology (2007) 4.14

Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? J Alzheimers Dis (2005) 3.78

Insulin rapidly stimulates tyrosine phosphorylation of a Mr-185,000 protein in intact cells. Nature (1985) 3.57

Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest (1999) 3.36

Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am J Pathol (2004) 3.24

Relation of diabetes to mild cognitive impairment. Arch Neurol (2007) 2.86

4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem (1997) 2.80

Increased risk of type 2 diabetes in Alzheimer disease. Diabetes (2004) 2.61

Diagnostic criteria for neuropathologic assessment of Alzheimer's disease. Neurobiol Aging (1997) 2.59

Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci U S A (2004) 2.54

Pleiotropic insulin signals are engaged by multisite phosphorylation of IRS-1. Mol Cell Biol (1993) 2.44

Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol (2006) 2.42

The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol (2005) 2.39

Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res (2007) 2.39

Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry (2005) 2.21

Oxidative alterations in Alzheimer's disease. Brain Pathol (1999) 2.21

Body mass index in midlife and risk of Alzheimer disease and vascular dementia. Curr Alzheimer Res (2007) 2.19

Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging (2005) 2.15

Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis (2005) 2.12

Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimers Dis (2005) 2.11

The phosphatidylinositol 3-kinase serine kinase phosphorylates IRS-1. Stimulation by insulin and inhibition by Wortmannin. J Biol Chem (1994) 2.09

The epidemiology of the dementias: an update. Curr Opin Psychiatry (2007) 2.05

Intranasal insulin improves memory in humans. Psychoneuroendocrinology (2004) 2.03

Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci (2003) 2.03

Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol (2002) 2.03

Cardiovascular risk factors and Alzheimer's disease. Curr Atheroscler Rep (2004) 2.00

New perspectives on Alzheimer's disease. Annu Rev Neurosci (1986) 1.95

Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm (Vienna) (1998) 1.90

Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem (1997) 1.88

Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry (2006) 1.88

Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis (2006) 1.82

Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol (2007) 1.76

Memory impairment in obese Zucker rats: an investigation of cognitive function in an animal model of insulin resistance and obesity. Behav Neurosci (2005) 1.76

Transient hypoxia causes Alzheimer-type molecular and biochemical abnormalities in cortical neurons: potential strategies for neuroprotection. J Alzheimers Dis (2003) 1.69

Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J Alzheimers Dis (2006) 1.65

The effect of borderline diabetes on the risk of dementia and Alzheimer's disease. Diabetes (2007) 1.62

Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease. Nat Clin Pract Neurol (2006) 1.57

Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci (1998) 1.56

Brain aging in very old men with type 2 diabetes: the Honolulu-Asia Aging Study. Diabetes Care (2006) 1.54

The IRS-1 signaling system. Trends Biochem Sci (1994) 1.53

Role of mitochondria in non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2007) 1.52

Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol (2004) 1.52

How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. Aging Cell (2004) 1.51

Genotoxicity of streptozotocin. Mutat Res (2002) 1.51

Type 2 diabetes and risk of cognitive impairment and dementia. Curr Neurol Neurosci Rep (2007) 1.50

Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. J Alzheimers Dis (2006) 1.48

Impaired brain development and hydrocephalus in a line of transgenic mice with liver-specific expression of human insulin-like growth factor binding protein-1. Growth Horm IGF Res (2000) 1.47

Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology (2003) 1.44

Update on non-alcoholic fatty liver disease in children. Clin Nutr (2007) 1.43

Diabetes mellitus and dementia. Diabetes Metab (2006) 1.39

Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem (2007) 1.37

Quantitation of cerebral atrophy in preclinical and end-stage Alzheimer's disease. Ann Neurol (1989) 1.36

Ethanol impairs insulin-stimulated neuronal survival in the developing brain: role of PTEN phosphatase. J Biol Chem (2003) 1.35

Studies of the effects of high fat diets on cognitive function in a rat model. Neurobiol Aging (2005) 1.34

Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease. J Neurol Sci (1997) 1.31

Intranasal insulin improves memory in humans: superiority of insulin aspart. Neuropsychopharmacology (2006) 1.31

Assessment of the pathological stages of Alzheimer's disease in thin paraffin sections: a comparative study. Dement Geriatr Cogn Disord (1998) 1.30

Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications. Adv Exp Med Biol (2004) 1.29

Synaptic pathology in Alzheimer's disease: immunological data for markers of synaptic and large dense-core vesicles. Neuroscience (1992) 1.28

The calpains in aging and aging-related diseases. Ageing Res Rev (2003) 1.28

Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis Assoc Disord (2006) 1.27

Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype. Ann N Y Acad Sci (2000) 1.27

Diabetes and brain aging: epidemiologic evidence. Curr Diab Rep (2005) 1.27

Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus. J Alzheimers Dis (2008) 1.26

Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway. J Neurochem (2006) 1.23

Neuropathological aspects of Alzheimer disease, Parkinson disease and frontotemporal dementia. Neurodegener Dis (2008) 1.20

Chronic gestational exposure to ethanol causes insulin and IGF resistance and impairs acetylcholine homeostasis in the brain. Cell Mol Life Sci (2006) 1.19

Can dementia be prevented? Brain aging in a population-based context. Annu Rev Public Health (2004) 1.18

Differential impact of cerebral white matter changes, diabetes, hypertension and stroke on cognitive performance among non-disabled elderly. The LADIS study. J Neurol Neurosurg Psychiatry (2007) 1.17

Intranasal insulin to improve memory function in humans. Neuroendocrinology (2007) 1.16

The clinical and biological relationship between Type II diabetes mellitus and Alzheimer's disease. Curr Alzheimer Res (2004) 1.14

Chronic gestational exposure to ethanol impairs insulin-stimulated survival and mitochondrial function in cerebellar neurons. Cell Mol Life Sci (2002) 1.12

Dementia of the Alzheimer type. Epidemiol Rev (2008) 1.10

Neuroinflammatory perspectives on the two faces of Alzheimer's disease. J Neural Transm (Vienna) (2003) 1.10

Bax protein expression is increased in Alzheimer's brain: correlations with DNA damage, Bcl-2 expression, and brain pathology. J Neuropathol Exp Neurol (1997) 1.09

Metabolic syndrome and NASH. Clin Liver Dis (2007) 1.08

Brain mitochondrial dysfunction as a link between Alzheimer's disease and diabetes. J Neurol Sci (2007) 1.07

Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease. Curr Alzheimer Res (2007) 1.06

Cortical synaptic changes and gliosis in normal aging, Alzheimer's disease and frontal lobe degeneration. Dementia (1996) 1.05

Insulin-mediated regulation of neuronal maturation. Science (1984) 1.03

Death and survival of neuronal cells exposed to Alzheimer's insults. J Neurosci Res (2002) 1.02

Recent advancement of understanding pathogenesis of type 1 diabetes and potential relevance to diabetic nephropathy. Am J Nephrol (2007) 1.02

Amyloid fibril toxicity in Alzheimer's disease and diabetes. Ann N Y Acad Sci (1996) 1.00

Defective IGF2 and IGF1R protein production in embryonic pancreas precedes beta cell mass anomaly in the Goto-Kakizaki rat model of type 2 diabetes. Diabetologia (2007) 1.00

Synaptic pathology of Alzheimer's disease. Ann N Y Acad Sci (1993) 0.99

Diabetic neuropathies in brain are induced by deficiency of BDNF. Neurotoxicol Teratol (2002) 0.99

Partial rescue of ethanol-induced neuronal apoptosis by growth factor activation of phosphoinositol-3-kinase. Alcohol Clin Exp Res (2000) 0.98

Insulin effects on CSF norepinephrine and cognition in Alzheimer's disease. Neurobiol Aging (2006) 0.98

Characterization of the toxic mechanism triggered by Alzheimer's amyloid-beta peptides via p75 neurotrophin receptor in neuronal hybrid cells. J Neurosci Res (2003) 0.97

Glucose metabolism and acetylcholine synthesis in relation to neuronal activity in Alzheimer's disease. Lancet (1980) 0.96

Ethanol impairs insulin-stimulated mitochondrial function in cerebellar granule neurons. Cell Mol Life Sci (2001) 0.95

Insulin-like growth factor system regulates oligodendroglial cell behavior: therapeutic potential in CNS. J Mol Neurosci (2008) 0.95

Intracerebroventricular injection of streptozotocin induces discrete local changes in cerebral glucose utilization in rats. Int J Dev Neurosci (1994) 0.95

Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? J Alzheimers Dis (2005) 3.78

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology (2010) 3.55

Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis (2005) 2.12

Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimers Dis (2005) 2.11

Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology (2004) 1.88

Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis (2006) 1.82

Antisense oligodeoxynucleotides directed against aspartyl (asparaginyl) beta-hydroxylase suppress migration of cholangiocarcinoma cells. J Hepatol (2003) 1.80

Alcohol and hepatitis C virus--interactions in immune dysfunctions and liver damage. Alcohol Clin Exp Res (2010) 1.77

The mitochondrial uncoupling protein-2 promotes chemoresistance in cancer cells. Cancer Res (2008) 1.71

Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J Alzheimers Dis (2006) 1.65

Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology (2006) 1.64

Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. J Hepatol (2008) 1.56

Wnt/Frizzled signaling in hepatocellular carcinoma. Front Biosci (2006) 1.50

Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology (2006) 1.49

Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. J Alzheimers Dis (2006) 1.48

Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma. Hepatology (2006) 1.44

Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. J Hepatol (2013) 1.40

Expression of uncoupling protein-2 in human colon cancer. Clin Cancer Res (2004) 1.37

Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma. J Hepatol (2005) 1.33

Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma. Cancer (2003) 1.32

Acute ethanol exposure inhibits insulin signaling in the liver. Hepatology (2007) 1.31

The human cervical cancer oncogene protein is a biomarker for human hepatocellular carcinoma. Cancer Res (2004) 1.30

Hepatitis C virus core protein stimulates hepatocyte growth: correlation with upregulation of wnt-1 expression. Hepatology (2005) 1.30

Insulin resistance in experimental alcohol-induced liver disease. J Gastroenterol Hepatol (2008) 1.28

Prevention of hepatocellular carcinoma. N Engl J Med (2004) 1.27

Potential role of PTEN phosphatase in ethanol-impaired survival signaling in the liver. Hepatology (2003) 1.26

Uncoupling protein-2 deficiency promotes oxidant stress and delays liver regeneration in mice. Hepatology (2004) 1.24

Insulin and insulin-like growth factor resistance with neurodegeneration in an adult chronic ethanol exposure model. Alcohol Clin Exp Res (2007) 1.23

Aspartyl-(asparaginyl)-beta-hydroxylase regulates hepatocellular carcinoma invasiveness. J Hepatol (2006) 1.22

Alcohol-induced disruption of endocrine signaling. Alcohol Clin Exp Res (2007) 1.21

Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. Curr Opin Investig Drugs (2009) 1.21

PPARdelta agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair. J Hepatol (2009) 1.20

Acute and chronic alcohol abuse modulate immunity. Alcohol Clin Exp Res (2006) 1.18

Acetaldehyde adducts in alcoholic liver disease. Oxid Med Cell Longev (2010) 1.18

Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease. J Hepatol (2012) 1.16

Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's disease. J Alzheimers Dis (2009) 1.15

Modulation of hepatitis B virus secretion by naturally occurring mutations in the S gene. J Virol (2004) 1.13

Role of the aspartyl-asparaginyl-beta-hydroxylase gene in neuroblastoma cell motility. Lab Invest (2002) 1.12

Hepatitis C virus and alcohol. Semin Liver Dis (2009) 1.08

Insulin resistance, ceramide accumulation, and endoplasmic reticulum stress in human chronic alcohol-related liver disease. Oxid Med Cell Longev (2012) 1.07

Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis. J Alzheimers Dis (2009) 1.07

Activation of p53 enhances apoptosis and insulin resistance in a rat model of alcoholic liver disease. J Hepatol (2010) 1.07

Lack of UCP2 reduces Fas-mediated liver injury in ob/ob mice and reveals importance of cell-specific UCP2 expression. Hepatology (2006) 1.07

Ethanol impaired neuronal migration is associated with reduced aspartyl-asparaginyl-beta-hydroxylase expression. Acta Neuropathol (2008) 1.06

Hepatitis C virus NS2 protein inhibits gene expression from different cellular and viral promoters in hepatic and nonhepatic cell lines. Virology (2003) 1.06

Chronic ethanol consumption impairs cellular immune responses against HCV NS5 protein due to dendritic cell dysfunction. Gastroenterology (2006) 1.04

Ethanol inhibition of aspartyl-asparaginyl-beta-hydroxylase in fetal alcohol spectrum disorder: potential link to the impairments in central nervous system neuronal migration. Alcohol (2009) 1.04

Differential growth factor regulation of aspartyl-(asparaginyl)-beta-hydroxylase family genes in SH-Sy5y human neuroblastoma cells. BMC Cell Biol (2006) 1.04

Human WISP1v, a member of the CCN family, is associated with invasive cholangiocarcinoma. Hepatology (2003) 1.03

Impairment of hepatitis B virus virion secretion by single-amino-acid substitutions in the small envelope protein and rescue by a novel glycosylation site. J Virol (2010) 1.02

Clinicopathological correlates of aspartyl (asparaginyl) beta-hydroxylase over-expression in cholangiocarcinoma. Cancer Detect Prev (2004) 1.01

Overexpression of insulin receptor substrate-1 and hepatitis Bx genes causes premalignant alterations in the liver. Hepatology (2009) 1.01

Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma. Hepatology (2002) 1.01

The liver-brain axis of alcohol-mediated neurodegeneration: role of toxic lipids. Int J Environ Res Public Health (2009) 1.00

Hepatitis C virus NS2 protein triggers endoplasmic reticulum stress and suppresses its own viral replication. J Hepatol (2010) 0.99

Role of aspartyl-(asparaginyl) beta-hydroxylase in placental implantation: Relevance to early pregnancy loss. Hum Pathol (2006) 0.99

Noncanonical Wnt11 inhibits hepatocellular carcinoma cell proliferation and migration. Mol Cancer Res (2010) 0.98

Limited therapeutic effect of N-acetylcysteine on hepatic insulin resistance in an experimental model of alcohol-induced steatohepatitis. Alcohol Clin Exp Res (2011) 0.98

Activated iNKT cells promote memory CD8+ T cell differentiation during viral infection. PLoS One (2012) 0.97

Uncoupling protein-2 modulates the lipid metabolic response to fasting in mice. Am J Physiol Gastrointest Liver Physiol (2008) 0.96

The p85beta regulatory subunit of PI3K serves as a substrate for PTEN protein phosphatase activity during insulin mediated signaling. Biochem Biophys Res Commun (2010) 0.96

Pharmacological inhibition of Frizzled-7 displays anti-tumor properties in hepatocellular carcinoma. J Hepatol (2010) 0.94

ATP luminescence-based motility-invasion assay. Biotechniques (2002) 0.94

Low density contrast agents for x-ray phase contrast imaging: the use of ambient air for x-ray angiography of excised murine liver tissue. Phys Med Biol (2008) 0.94

Rat strain differences in susceptibility to alcohol-induced chronic liver injury and hepatic insulin resistance. Gastroenterol Res Pract (2010) 0.94

Aspartyl-(asparaginyl) beta-hydroxylase, hypoxia-inducible factor-alpha and Notch cross-talk in regulating neuronal motility. Oxid Med Cell Longev (2010) 0.94

Enhanced colon tumor induction in uncoupling protein-2 deficient mice is associated with NF-kappaB activation and oxidative stress. Carcinogenesis (2006) 0.94

Insulin and insulin-like growth factor resistance in alcoholic neurodegeneration. Alcohol Clin Exp Res (2008) 0.94

A cell-surface β-hydroxylase is a biomarker and therapeutic target for hepatocellular carcinoma. Hepatology (2014) 0.94

Vaccination with protein-transduced dendritic cells elicits a sustained response to hepatitis C viral antigens. Gastroenterology (2006) 0.93

Chimeric constructs between two hepatitis B virus genomes confirm transcriptional impact of core promoter mutations and reveal multiple effects of core gene mutations. Virology (2009) 0.93

Peroxisome proliferator-activated receptor agonist treatment of alcohol-induced hepatic insulin resistance. Hepatol Res (2011) 0.93

Prognostic value of humbug gene overexpression in stage II colon cancer. Hum Pathol (2006) 0.92

Nanomaterials for X-ray imaging: gold nanoparticle enhancement of X-ray scatter imaging of hepatocellular carcinoma. Nano Lett (2011) 0.92

Insulin resistance, ceramide accumulation and endoplasmic reticulum stress in experimental chronic alcohol-induced steatohepatitis. Alcohol Alcohol (2012) 0.91

Upregulation of T-cell factor-4 isoform-responsive target genes in hepatocellular carcinoma. Liver Int (2013) 0.91

Ceramide-mediated insulin resistance and impairment of cognitive-motor functions. J Alzheimers Dis (2010) 0.91

Insulin signaling through insulin receptor substrate 1 and 2 in normal liver development. Gastroenterology (2003) 0.91

Mechanisms of alcohol-induced tissue injury. Alcohol Clin Exp Res (2003) 0.91

Induction of angiopoietin-2 gene expression by COX-2: a novel role for COX-2 inhibitors during hepatocarcinogenesis. J Hepatol (2005) 0.90

Prognostic value of aspartyl (asparaginyl)-beta-hydroxylase/humbug expression in non-small cell lung carcinoma. Hum Pathol (2009) 0.90

Chronic alcohol-induced hepatic insulin resistance and endoplasmic reticulum stress ameliorated by peroxisome-proliferator activated receptor-δ agonist treatment. J Gastroenterol Hepatol (2013) 0.89

T1846 and A/G1913 are associated with acute on chronic liver failure in patients infected with hepatitis B virus genotypes B and C. J Med Virol (2011) 0.89

Identification of T-cell factor-4 isoforms that contribute to the malignant phenotype of hepatocellular carcinoma cells. Exp Cell Res (2011) 0.89

Glycine decarboxylase mediates a postbinding step in duck hepatitis B virus infection. J Virol (2004) 0.89

Human aspartyl (asparaginyl) beta-hydroxylase monoclonal antibodies: potential biomarkers for pancreatic carcinoma. Pancreas (2002) 0.88

Role of central nervous system insulin resistance in fetal alcohol spectrum disorders. J Popul Ther Clin Pharmacol (2010) 0.88

Type 1 interferon augments DNA-based vaccination against hepatitis C virus core protein. J Med Virol (2005) 0.88

High fat diet induced hepatic steatosis and insulin resistance: Role of dysregulated ceramide metabolism. Hepatol Res (2011) 0.88

Points of therapeutic intervention along the Wnt signaling pathway in hepatocellular carcinoma. Anticancer Agents Med Chem (2011) 0.88

Loss of the SxxSS motif in a human T-cell factor-4 isoform confers hypoxia resistance to liver cancer: an oncogenic switch in Wnt signaling. PLoS One (2012) 0.86

Angiogenic switch as a molecular target of malignant tumors. J Gastroenterol (2003) 0.86

Generation and characterization of an immunogenic dendritic cell population. J Immunol Methods (2008) 0.86

Cytokine dependent and independent iNKT cell activation. Cytokine (2010) 0.86

Early growth response-1 transcription factor promotes hepatic fibrosis and steatosis in long-term ethanol-fed Long-Evans rats. Liver Int (2012) 0.85

Antibody-directed therapy for human hepatocellular carcinoma. Gastroenterology (2004) 0.84

Weight loss amelioration of non-alcoholic steatohepatitis linked to shifts in hepatic ceramide expression and serum ceramide levels. Hepatol Res (2011) 0.84

Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death. Mol Cancer Ther (2009) 0.84

Ethanol inhibits antigen presentation by dendritic cells. Clin Vaccine Immunol (2011) 0.84

Chronic ethanol diet increases regulatory T-cell activity and inhibits hepatitis C virus core-specific cellular immune responses in mice. Hepatol Res (2013) 0.84